Clinical trial NCT02145507: Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Official title: Clinical Investigation to Evaluate the Haemonetics LeukoSep Leukocyte Reduction Filtration System for Whole Blood With CPD Anticoagulant and SOLX Additive - Pivotal Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Blood Donors
Keywords: Leukoreduction
Red Blood Cell post-leukoreduction recovery
Packed red blood cell post storage hemolysis
Red blood cell recovery
Plasma clotting factors
2,3-DPG rejuvenation
Lead sponsor: Haemonetics Corporation
Sponsor class: INDUSTRY
First posted: 2014-05-23
Enrollment: 170
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study will evaluate a new blood collection and filtration system that is intended to be used to collect, filter, separate and store red blood cells and, separately, plasma. The new blood collection and filtration system will be compared to an already-approved and currently used system. Further, this study will evaluate new processing conditions relative to the individual components of the collection and filtration system. All study participants will donate two units of whole blood with individual units being donated at least 56 days apart. One unit of whole blood will be donated with the new system, and the other unit will be collected with the already-approved system. A subset of the donors (approximately 24 of the 120 participants) will have a small quantity of their red blood cells injected back into their body 42-days after they were donated in order to evaluate how well the red blood cells survive. Blood and blood products from all donors will be analyzed the day of collection and after storage (plasma after at least 30 days of storage and red blood cells after exactly 42 days of storage).

Detailed description: In vitro and in vivo performance of SOLX® RBCs produced with the modified SOLX® System will be used to demonstrate the acceptability of both the proposed product modification and expanded indications. To accomplish this, the study will require a total of 120 evaluable donors completing the study. Enrolled donors will be assigned to either of two study arms. Each study arm will entail a randomized, paired, 2-x-2 crossover design where every study donor (n = 60 evaluable study donors who complete the study per arm) will donate a total of two whole blood units with individual units being donated at least 56 days (8 weeks) apart. One unit will be collected with the investigational product (IP) and the other unit will be collected with the control product (CP). The order in which the IP and the CP will be used to collect, filter and store the whole blood and appropriate blood products (within the context of the crossover design) will be randomized.

Each of the two study arms will evaluate outcomes resulting from different storage, filtration and processing conditions:

* Arm 1 will entail holding whole blood units at 20-24°C after collection for ≥ 20 hours (IP) or ≥ 6 hours (CP) prior to initiating room temperature filtration. Following room temperature centrifugation and subsequent separation, SOLX® PRBC will be placed at 1-6°C and plasma placed at ≤ -18°C within 24 hours (IP) or within 8 hour (CP) of collection. The first donation will occur with product indicated per randomization and the second donation will occur with product alternate to the randomization. Arm 1 will further entail an in vivo double-radiolabelled autologous RBC recovery substudy (n = 20-24, paired IP and CP data will be collected) and an evaluation of pre- and post-rejuvenation PRBC 2,3-DPG levels (all IP and CP units). The in vivo substudy and rejuvenation evaluation is limited to only Arm 1 and is not included in Arm 2.
* Arm 2 will entail holding whole blood units at 1-6°C after collection for ≥ 66 hours (both IP and CP) prior to initiating cold filtration. Following refrigerated centrifugation and subsequent separation, SOLX® PRBCs will be placed at 1-6°C within 72 hours of collection (both IP and CP). Plasma will not be evaluated for this arm and will be discarded. The first donation will occur with product indicated per randomization and the second donation will occur with product alternate to the randomization.

For each study arm that does not meet the protocol-defined in vitro acceptance criteria for exactly 1 unit, an additional 71 evaluable donors will be enrolled, thus increasing the number of evaluable enrolled donors completing the respective study arm to 131 donors. Only those acceptance criteria endpoints that were not met within their respective study arm will be evaluated and neither matched/paired crossover controls nor in vivo RBC recovery (Arm 1 In vivo substudy) will be evaluated. If all protocol defined in vitro acceptance criteria are met or \> 1 subject does not meet the protocol defined in vitro acceptance criteria relative to a specific study arm, then no enrollment will occur relative to the same study arm.

Eligibility criteria: Inclusion Criteria:

* Age - Study donor must be ≥ 18 years of age
* Weight - Study donor must be ≥ 110 pounds
* Temperature - Study donor's body temperature must be ≤ 37.5°C / 99.5°F (oral)
* Hemoglobin - Study donor's hemoglobin must be ≥12.5 g/dL
* Hematocrit - Study donor's hematocrit must be ≥ 38%. Donor Eligibility - Study donor must meet all criteria per respective site's Research Blood Donation Record (BDR)
* Prior Donation - Study donor's most recent single RBC unit donation must have been ≥56 days prior to study donation. Study donor's most recent double RBC unit donation must have been ≥ 112 days prior to study donation
* Informed Consent - Study donor must have consented to study participation by reviewing and having expressed understanding the site-respective IRB-approved informed consent form prior to undergoing any study related procedures
* Blood-borne Pathogens - Study donor's testing results from collected blood does not indicate a risk of transfusion-transmitted disease (TTD)
* Adverse Events - Study donors must agree to report adverse events from the time of signing the informed consent to twenty-four hours following the end of their active study involvement
* Pregnancy - Female study donors must not be pregnant, expected to be pregnant or breastfeeding. Only female donors who participate in the in vivo portion of the study: Women of child-bearing age must not be pregnant as determined by a negative pregnancy test prior to each re-infusion. If acceptable by local procedures, post-menopausal or surgically sterile women may be exempt from the pregnancy testing requirement

Exclusion criteria:

-Failure to meet one or more of the above criteria

Primary outcomes:
measure: Red Blood Cell Post-filtration Recovery
timeFrame: Arm and product dependent (< 8 hours, 20-24 hours, 66-72 hours post collection)
measure: Residual Leukocyte Count
timeFrame: <8 hours and 20-24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Hoxworth Blood Center
state: Ohio
city: Norfolk
country: United States
facility: American Red Cross Mid-Atlantic Region Blood Services
state: Virginia
Study officials:
affiliation: ARC Mid-Atlantic Region Blood Services
name: Lou A Maes, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hoxworth Blood Center
name: Jose Cancelas, MD
role: PRINCIPAL_INVESTIGATOR
References: